IGF2BP3 as a Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma
Cells · 07.08.2025 · 14 (15) · 1222
DOI: 10.3390/cells14151222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 07.08.2025. Verfasst von Feiming Hu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Air Force Medical University, No. 169, Changle West Road, Xi'an 710032, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Biomarkers, Tumor, RNA-Binding Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China, The Young Talent Fund of Association for Science and Technology in Shaanxi, China, Air Force Medical University research project.
Abstract (Originalsprache)
RNA-binding proteins (RBPs), particularly IGF2BP3, play critical but underexplored roles in lung adenocarcinoma (LUAD). This study investigated IGF2BP3′s clinical and functional significance using single-cell/RNA sequencing, validated by qPCR, Western blot, and immunohistochemistry. The results show IGF2BP3 was significantly upregulated in LUAD tissues and associated with advanced-stage, larger tumors, lymph node metastasis, and poor prognosis. A prognostic nomogram confirmed its independent predictive value. Functionally, IGF2BP3 knockdown suppressed proliferation, and induced G2/M arrest and apoptosis. GSEA linked high IGF2BP3 to cell cycle activation and low expression to metabolic pathways. Notably, high IGF2BP3 correlated with immune evasion markers (downregulated CD4+ effector T cells, upregulated Th2 cells), while TIDE analysis suggested a better immunotherapy response in low-expressing patients. Drug screening identified BI-2536 as a potential therapy for low-IGF2BP3 cases, supported by strong molecular docking affinity (−7.55 kcal/mol). These findings establish IGF2BP3 as a key driver of LUAD progression and a promising target for immunotherapy and precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Air Force Medical University, No. 169, Changle West Road, Xi'an 710032, China.
- Yan'an Key Laboratory of Microbial Drug Innovation and Transformation, School of Basic Medicine, Yan'an University, Yan'an 716000, China.
- Military Medical Innovation Center, Air Force Medical University, Xi'an 710032, China.
- School of Basic Medicine, Air Force Medical University, No. 169, Changle West Road, Xi'an 710032, China.
ORCID-Profile: Dongbo Jiang, Shuya Yang
Förderung
- The National Natural Science Foundation of China
- The Young Talent Fund of Association for Science and Technology in Shaanxi, China
- Air Force Medical University research project
- National Natural Science Foundation of China
- Young Talent Fund of Association for Science and Technology in Shaanxi, China
Zitieren
APA
Hu, F., Hu, C., He, Y., Guo, L., Sun, Y., Han, C., Zhang, X., Ren, J., Han, J., Wang, J., Zhang, J., Sun, Y., Cai, S., Jiang, D., Yang, K., & Yang, S. (2025). IGF2BP3 as a Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma. Cells, 14(15), 1222. https://doi.org/10.3390/cells14151222
Vancouver
Hu F, Hu C, He Y, Guo L, Sun Y, Han C, et al. IGF2BP3 as a Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma. Cells. 2025;14(15):1222. doi:10.3390/cells14151222
BibTeX
@article{Hu2025,
author = {Hu, Feiming and Hu, Chenchen and He, Yuanli and Guo, Lin and Sun, Yuanjie and Han, Chenying and Zhang, Xiyang and Ren, Junyi and Han, Jinduo and Wang, Jing and Zhang, Junqi and Sun, Yubo and Cai, Sirui and Jiang, Dongbo and Yang, Kun and Yang, Shuya},
title = {IGF2BP3 as a Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma},
journal = {Cells},
year = {2025},
volume = {14},
number = {15},
pages = {1222},
doi = {10.3390/cells14151222}
}
EUVIMED